XML 53 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration and License Agreements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Jun. 14, 2022
Apr. 09, 2021
Jan. 06, 2021
Jul. 31, 2022
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Aug. 31, 2021
Collaboration and License Agreements [Line items]                    
Equity method investments                 $ 3,751,000  
Revenue         $ 7,363,000 $ 24,036,000 $ 14,500,000 $ 109,190,000    
Deferred revenue         $ 48,405,000   $ 48,405,000   $ 21,244,000  
Common stock, shares issued         111,745,219   111,745,219   61,712,577  
Proceeds from offering of common stock, net of issuance costs             $ 49,345,000 18,130,000    
Prepaid expenses         $ 12,292,000   12,292,000   $ 17,434,000  
Research and development         19,959,000 25,940,000 62,867,000 88,768,000    
Revenue recorded included in deferred revenue             10,800,000      
Servier | Program Purchase Agreement                    
Collaboration and License Agreements [Line items]                    
Research and development   $ 1,250,000                
Waiver of milestone payment   $ 18,750,000                
Research and Development Arrangement                    
Collaboration and License Agreements [Line items]                    
Prepaid Expense and Other Assets         11,200,000   11,200,000      
Prepaid expenses         4,200,000   4,200,000      
Other Assets         7,000,000.0   7,000,000.0      
Research and development             1,700,000      
Research and Development Arrangement | Current Liabilities                    
Collaboration and License Agreements [Line items]                    
Deferred revenue         30,100,000   30,100,000      
Research and Development Arrangement | Novartis Pharma AG                    
Collaboration and License Agreements [Line items]                    
Upfront cash payment $ 50,000,000.0                  
Milestone payments to be received for additional targets $ 1,400,000,000                  
Obligation to pay royalties expiry date 10 years                  
Transaction price from the Stock Purchase Agreement $ 13,400,000                  
Revenue         3,600,000   3,600,000      
Deferred revenue related to agreement         60,000,000.0   $ 60,000,000.0      
Research and Development Arrangement | Novartis Pharma AG | Stock Purchase Agreement                    
Collaboration and License Agreements [Line items]                    
Upfront cash payment       $ 50,000,000.0            
Sale of stock, number of shares issued in transaction 12,407,440                  
Aggregate purchase price $ 25,000,000.0                  
Sale of stock, price per share $ 2.01                  
Percentage of premium over the volume-weighted-average-price of the company’s common stock 20.00%                  
Upfront Compensation $ 75,000,000.0                  
Equity upon the issuance of the shares 11,600,000                  
Transaction price allocated to the revenue arrangement $ 63,400,000                  
Sale of stock, description of transaction             Pursuant to the Novartis Stock Purchase Agreement, subject to certain exceptions, Novartis may not sell the Novartis Shares without the Company’s approval for a period of two years following the Novartis Effective Date. In addition, for a period of two years following the Novartis Effective Date, Novartis and its affiliates may not (a) effect or otherwise participate in, directly or indirectly, any acquisition of any of our securities or material assets, any tender offer or exchange offer, merger or other business combination or change of control involving the Company, any recapitalization, restructuring, liquidation, dissolution or other extraordinary transaction with respect to the Company, or any solicitation of proxies or consents to vote any of the Company’s securities or (b) act with any other person, or publicly disclose any intention, to do any of the foregoing. The Novartis Stock Purchase Agreement also contains customary representations, warranties, and covenants of both parties.      
Research and Development Arrangement | Eli Lilly and Company                    
Collaboration and License Agreements [Line items]                    
Upfront cash payment     $ 100,000,000.0              
Milestone payments to be received for additional targets     420,000,000.0              
Transaction price from the Stock Purchase Agreement     7,300,000              
Revenue         3,800,000 $ 4,900,000 $ 10,900,000 15,600,000    
Deferred revenue related to agreement         78,900,000   78,900,000   88,300,000  
Research and Development Arrangement | Eli Lilly and Company | Current Liabilities                    
Collaboration and License Agreements [Line items]                    
Deferred revenue         18,300,000   18,300,000   21,200,000  
Research and Development Arrangement | Eli Lilly and Company | Stock Purchase Agreement                    
Collaboration and License Agreements [Line items]                    
Upfront Compensation     135,000,000.0              
Equity upon the issuance of the shares     27,700,000              
Transaction price allocated to the revenue arrangement     $ 107,300,000              
Common stock, shares issued     3,762,190              
Proceeds from offering of common stock, net of issuance costs     $ 35,000,000.0              
Research and Development Arrangement | iECURE                    
Collaboration and License Agreements [Line items]                    
Investment in equity securities         0   0     $ 500,000
Prepaid Expense and Other Assets                   $ 17,400,000
Development And Commercial License Agreement | Servier                    
Collaboration and License Agreements [Line items]                    
Deferred revenue related to agreement         $ 0   0   $ 0  
Revenue recorded included in deferred revenue             $ 0 $ 72,900,000